The plasma therapy market size was valued at USD 205.15 million in 2019 and is expected to grow with a CAGR of 14.8%.
Plasma therapy aims to use blood-derived antibodies to treat persistent, life-threatening diseases. Plasma therapy has recently been shown to be a successful treatment for increasing life expectancies and survival rates. Accidental blood loss is rising, and rising healthcare costs fuel market expansion. Effective plasma-derived treatments are required globally to treat rare diseases for which modern medicine has no cure. Many medical professionals are actively implementing plasma therapy as a standard practice to treat the ever-growing list of orthopedic and other therapeutic conditions. The use of plasma therapy on COVID-19 patients has recently received FDA approval. The market for plasma-derived therapy has significantly benefited from the treatments discovered for numerous diseases. It is anticipated to continue to expand similarly over the next few years. Due to the massive demand for plasma-derived therapies around the world that were successful in showing a significant result in treating the complications that were created in the body of the individual about the infection, the coronavirus pandemic's outbreak had a significant impact on the growth of this market.
|Market Size||USD 205.15 million in 2019|
|Fastest Growing Market||Asia Pacific|
|Largest Market||North America|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends|
There has been a significant rise in demand for plasma-derived therapies. Strong growth in immunoglobulin demand resulted in positive market expansion on a global scale. The increase in cases of various immunodeficiency disorders worldwide is the cause of the rising demand. A group of 300 diseases known as primary immunodeficiency is characterized by recurrent chronic infections, autoimmune disease, allergy, or inflammation. These infections are a result of immune system-affecting genetic alteration. Such disorders can be treated using specialized immunoglobulin therapies or immunoglobulin replacement therapy. The market is driven due to the rising demand for these treatments and the consequent increase in immunoglobulin production by these processes. Due to the rising prevalence of these immunodeficiency disorders and other diseases, there was a rise in the demand for therapies derived from plasma, which helped the global market growth.
This procedure involves dissecting plasma into different individual proteins for clinical use, including albumin, immunoglobulin, coagulation factor, and protease inhibitor. The major market participants have plasma fractionation facilities from which they can extract these proteins. The current need for plasma-derived therapies has prompted the development of several technologies that can speed up the procedure. For instance, GEA provided new separator technology to Biopharma S.A. in April 2021 for use in the company's new plant in Bila Tserkva, Ukraine. According to reports, the Rika Plasma Donation System is a cutting-edge automated technology created to satisfy the rising demand for plasma-derived therapies. Over the forecast period, the market will have more growth opportunities thanks to the ongoing efforts of various players to introduce technologies for the plasma fractionation process.
For various plasma-driven therapies, many recombinant substitutes have been created recently. Recombinant products are used as preventative measures and are less immunogenic than those made from plasma. Additional longer-acting replacement factors are being developed in addition to these. Significant advantages of the products include less frequent administration and improved prophylactic performance. Thus, a significant factor limiting the use of plasma products is the growing use of recombinant factors and their increased use in prophylactic therapies. Recombinant products are made by expressing identical proteins from genetically modified cells. They are a safer alternative to plasma-derived products because they prevent the potential for infectious diseases from being transmitted through the blood.
Human plasma is used to produce plasma-derived medicinal products (PDMPs). Albumin, immunoglobulins, and coagulation factors are some of these products. Numerous PDMP products were included in the model list of essential medications created by the World Health Organization (WHO). This initiative highlighted these drugs as being reliable and secure for treating severe conditions in the healthcare system. The high demand for plasma-derived products drives up the demand for these procedures, fueling the expansion of the market. For instance, immunoglobulin can treat primary immunodeficiency diseases by replenishing the secondary IgG serotype antibodies. Plasma therapies are crucial for severe deficiencies and play a significant role in prenatal and intensive care. Demand increased as plasma-derived therapies emerged as a potential cure for the new illness. Major corporations launched several R&D projects in response to the spike in demand to launch products and meet the demand on a global scale.
The global plasma therapy market is bifurcated into four regions: North America, Europe, Asia-Pacific, and LAMEA.
North America is the most significant global plasma therapy market shareholder and is expected to grow at a CAGR of 13.6% during the forecast period. The U.S. and Canada are included in the analysis of the plasma therapy market in North America. This is a result of both an increase in the prevalence of respiratory disorders and increased awareness of the many benefits of plasma among North American citizens. The existence of significant players, a rise in the consumption of immunoglobulin, an increase in the number of immunoglobulin collection facilities, and the availability of plasma as a result of the sustainability of plasma distribution and collection all contribute to the regional market's expansion. Due to the rising use of plasma therapy in therapeutics and the rising number of people suffering from orthopedic injuries, North America currently dominates the plasma therapy market. The presence of major players, a robust healthcare infrastructure, a supportive regulatory environment, and government funding support the regional market. The market has grown significantly due to recent initiatives by the government and private organizations to support the therapeutic system.
Asia Pacific is expected to grow at a CAGR of 14.42% during the forecast period. The Asia-Pacific plasma therapy market analysis includes China, India, Japan, Australia, and the rest of Asia-Pacific. The plasma therapy market is anticipated to expand fastest during the forecast period in Asia-Pacific. The market is growing due to increased cosmetic procedures and medical tourism in South Korea, Thailand, and India. Japan dominates the plasma therapy market in the Asia-Pacific region thanks to numerous companies producing and distributing medicines made from plasma. The nation established the Japan Blood Products Organization in 2012 to guarantee a consistent, secure, and self-sufficient supply of pharmaceuticals derived from plasma. To guarantee a sufficient supply of blood plasma across the nation, the organization encourages people to donate blood. On the other hand, players in the plasma therapy market have lucrative opportunities in India.
The market is segmented by type, source, application, and end user.
Based on type, the global market is bifurcated into pure platelet-rich plasma, leukocyte-rich PRP, pure platelet-rich fibrin, leukocyte-rich fibrin, and plasma proteins.
The pure platelet-rich plasma segment is the highest contributor to the market and is expected to grow at a CAGR of 13.8% during the forecast period. Due to its widespread use in cosmetic, general, cardiovascular, and wound healing surgeries, the pure platelet-rich plasma segment had the largest market share. Pure platelet-rich plasma therapy lowers the risk of post- and preoperative bleeding while promoting the regeneration of ligament and tendon fibers and soft tissue healing. As a result, it is regarded as one of the most important treatment options for controlling several chronic diseases.
Based on the source, the global market is bifurcated into autologous and allogeneic.
The autologous segment is the highest contributor to the market and is expected to grow at a CAGR of 14.53% during the forecast period. Compared to allogenic, it has a low risk of disease transmission and eliminates the expense of clinical analysis for blood-borne illnesses. The use of autologous PRP, a blood product, in clinical practice is expanding. The need for strict donor selection and testing criteria is further prompted by the fact that the allogenic plasma source is, on the other hand, extracted from the donor's blood using aphaeresis technology.
Based on application, the global plasma therapy market is bifurcated into orthopedic, chronic infectious diseases, dermatology, dental, cardiac muscle injury, and nerve injury.
The orthopedic segment is the highest contributor to the market and is expected to grow at a CAGR of 14.05% during the forecast period. Plasma therapy treats various orthopedic conditions, including rotator cuff, quadriceps, hamstring, Achilles tendon, and tennis elbow injuries. This is because it lowers the likelihood of recurrence. Therefore, the market growth is driven by the increasing use of plasma therapy in orthopedics. On the other hand, the dermatology segment is anticipated to experience significant growth during the forecast period. One of the most popular nonsurgical methods for facial rejuvenation is plasma therapy. The procedure uses the patient's blood to promote the production of new cells, enhance the appearance and texture of the skin, and replenish lost facial volume.
Based on end users, the global market is bifurcated into hospitals & clinics and research institutions.
The hospitals & clinics segment is the highest contributor to the market and is expected to grow at a CAGR of 14.39% during the forecast period. The segment for hospitals and clinics had the largest revenue share. The segment is anticipated to experience significant growth due to the increased off-label use of plasma fractionation products in hospitals to treat various diseases, improved infrastructure, and healthcare services. Furthermore, there is a high demand for plasma fractionation products due to the complex disorders that can be treated in contemporary clinical settings.
Currently, the world is battling the newly emerged strain, coronavirus, which has no definitive treatment. A similar picture of lack of definitive therapy can be traced in the history of medical science during the Ebola outbreak, where the World Health Organization (WHO) directed the use of convalescent plasma (CP) therapy to control its prevalence. Today, plasma therapy is used as one of the methods to treat COVID 19 patients. Recently, the U.S. FDA approved the use of plasma therapy for critically ill COVID-19 patients, further driving the market growth.